Graf Akcie ADMS (Adamas Pharmaceuticals Inc). Diskuze k akciím ADMS. Aktuální informace ADMS.

Základní informace o společnosti Adamas Pharmaceuticals Inc (Akcie ADMS)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 366.44M
Hodnota podniku (EV) 260.85M
Tržby 82.469M
EBITDA -41.76
Zisk -55.11
Růst v tržbách Q/Q 16.91 %
Růst v tržbách Y/Y 29.76 %
P/E (Cena vůči ziskům) N/A
Forward P/E 24.40
EV/Sales 3.16
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 4.44
P/FCF N/A
Price/Book -7.33
Účetní hodnota na akcii -1.10
Hotovost na akcii 1.84
FCF vůči ceně -14.04 %
Počet zaměstnanců 138
Tržba na zaměstnance 597.601k
Profit margin -77.09 %
Operating margin -51.44 %
Gross margin 97.26 %
EBIT margin -50.09 %
EBITDA margin -50.63 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst -27.03 %
EPS - Očekávaný růst příští rok -47.62 %
Return on assets -38.49 %
Return on equity 266.57 %
ROIC -30.77 %
ROCE -32.07 %
Dluhy/Equity -3.40
Čistý dluh/EBITDA -3.64
Current ratio 5.30
Quick Ratio 4.94
Volatilita 4.85
Beta 0.29
RSI 83.00
Cílová cena analytiků 9
Známka akcie (dle analytiků) N/A
Insider ownership 2.37 %
Institutional ownership 53.73 %
Počet akcií 45.596M
Procento shortovaných akcií 6.04 %
Short ratio 8.11 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2014
Země United States

Finanční výsledky akcie ADMS

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$54.637$34.046$0.571$0.572$1.916$55.846$71.095$37.471
Cost Of Goods Sold$2.469$0.633$0.017-----
Gross Profit$52.168$33.413$0.554$0.572$1.916$55.846$71.095$37.471
Research And Development Expenses$30.034$39.3$27.168$31.23$35.895$21.86$7.41$9.192
SG&A Expenses$114.369$109.135$61.312$30.326$23.458$15.472$6.667$8.33
Other Operating Income Or Expenses--------
Operating Expenses$146.872$149.068$88.497$61.556$59.353$37.332$14.077$17.522
Operating Income$-92.235$-115.022$-87.926$-60.984$-57.437$18.514$57.018$19.949
Total Non-Operating Income/Expense$-12.951$-15.977$-3.294$0.811$0.363$-0.917$-4.906$-1.913
Pre-Tax Income$-105.186$-130.999$-91.22$-60.173$-57.074$17.597$52.112$18.036
Income Taxes--$-1.73$-0.115$-5.272$7.374$1.191$0.3
Income After Taxes$-105.186$-130.999$-89.49$-60.058$-51.802$10.223$50.921$17.736
Other Income--------
Income From Continuous Operations$-105.186$-130.999$-89.49$-60.058$-51.802$10.223$50.921$17.736
Income From Discontinued Operations--------
Net Income$-105.186$-130.999$-89.49$-60.058$-51.802$8.968$33.068$11.441
EBITDA$-92.24$-114.607$-86.276$-60.477$-56.127$17.308$57.084$19.99
EBIT$-92.235$-115.022$-87.926$-60.984$-57.437$18.514$57.018$19.949
Basic Shares Outstanding282723221815109
Shares Outstanding2827232218171210
Basic EPS$-3.80$-4.87$-3.97$-2.77$-2.86$0.60$3.48$1.21
EPS - Earnings Per Share$-3.80$-4.87$-3.97$-2.77$-2.86$0.53$2.99$1.17
# 2020 2019 2018 2017 2016 2015
Current Ratio5.57829.407410.789112.00739.58649.8467
Long-term Debt / Capital1.00720.56650.6082---
Debt/Equity Ratio-143.01791.32531.5523---
Gross Margin95.481198.140897.0228100100100
Operating Margin-168.8142-337.8429-15398.6-10661.54-2997.75633.1519
EBIT Margin-168.8142-337.8429-15398.6-10661.54-2997.75633.1519
EBITDA Margin-168.8233-336.6239-15109.63-10572.9-2929.38430.9924
Pre-Tax Profit Margin-192.5179-384.7706-15975.48-10519.75-2978.8131.5099
Net Profit Margin-192.5179-384.7706-15672.5-10499.65-2703.65316.0585
Asset Turnover0.33690.1450.00310.0040.01490.3465
Inventory Turnover Ratio0.46880.12360.01---
Receiveable Turnover9.46926.17781.55590.72041.4922106.5763
Days Sales In Receivables38.546259.0823234.5972506.6609244.60333.4248
ROE - Return On Equity11778.59-145.7406-135.3326-45.4355-44.5856.9509
Return On Tangible Equity11779.08-145.7407-135.3326-45.4355-44.5856.9509
ROA - Return On Assets-64.8664-55.7884-48.0674-42.154-40.23686.3422
ROI - Return On Investment-84.2965-63.1802-53.0239-45.4355-44.5856.9509
Book Value Per Share-0.03193.27642.83556.00456.27878.3798
Operating Cash Flow Per Share0.9579-0.914-0.74850.3927-4.2314-0.6454
Free Cash Flow Per Share0.9968-0.8979-0.72940.3951-4.2334-0.7065

Porovnání s konkurencí: Akcie ADMS

Společnost P/E PEG Růst v tržbách (roční) Růst v EPS Return on equity P/B Profit margin
ADMS N/A N/A 29.76 % -47.62 % 266.57 % -7.33 -77.09 %
Akcie ABBV 29.80 1.28 48.31 % 14.49 % 48.79 % 14.67 10.08 %
Akcie GSK 16.60 3.36 N/A % -14.00 % 29.69 % 4.85 16.86 %
Akcie MRK 35.60 1.38 2.87 % 13.14 % 19.42 % 7.90 14.72 %
Akcie SUPN 16.35 0.37 34.57 % -68.92 % 13.39 % 2.21 24.39 %
Akcie ZGNX N/A N/A 801.95 % -11.11 % -70.65 % 2.47 -1,534.73 %

Nedávné obchody insiderů: Akcie ADMS

Jméno Obchod Cena Objem
Rajiv Patni
Chief Medical Officer
Prodej
20 Mar 2019
$8.00 $18,992
Alfred G Merriweather
Chief Financial Officer
Prodej
20 Mar 2019
$7.99 $6,847
Jennifer J Rhodes
General Counsel
Prodej
20 Jun 2019
$5.35 $5,029
Christopher B Prentiss
Chief Financial Officer
Prodej
22 Jul 2019
$6.00 $6,492
David L Mahoney
Director
Option
17 Sep 2019
$1.76 $58,664
Alfred G Merriweather
Chief Financial Officer
Prodej
20 Sep 2019
$6.91 $10,945
Christopher B Prentiss
Chief Financial Officer
Prodej
21 Jan 2020
$5.92 $7,512
Christopher B Prentiss
Chief Financial Officer
Prodej
2 Nov 2020
$3.21 $6,581
Christopher B Prentiss
Chief Financial Officer
Prodej
20 Jan 2021
$4.41 $11,598
Vijay Shreedhar
Chief Commercial Officer
Prodej
1 Feb 2021
$6.39 $28,844
Christopher B Prentiss
Chief Financial Officer
Prodej
1 Feb 2021
$6.36 $24,302

Diskuze k akciím ADMS